PneumoWave Takes Part in UK Government’s Reducing Drug Deaths Innovation Challenge
[Glasgow, Scotland – Thursday 31st October, 2024] https://www.gov.uk/government/news/virtual-reality-and-wearable-technology-pilot-to-cut-drug-deaths Government awards £12 million to research projects across the UK that are researching innovative technology to support
PneumoWave, King’s College London, Uniting MSIC Sydney and Royal Melbourne Hospital Publish Protocol for Observational Study in Supervised Injecting Facility
[Glasgow, Scotland – Monday 23rd September, 2024] https://www.researchprotocols.org/2024/1/e57367 A joint paper was published in JMIR Research Protocols, vol 13 (2024), detailing the OD-SEEN (Overdose Sensor
PneumoWave Achieves Major Milestones with ISO13485:2016 Certification and UKCA Class 1 Registration.
PneumoWave, an innovator in the fight against the opioidepidemic, is proud to announce that it has achieved ISO 13485:2016 certification and has registered aversion of its technology as a Class 1 UKCA device.
Top 10 Medical Device Trends in 2024 | PneumoWave develops a Smart Biosensor
UK-based startup PneumoWave devises a chest-worn smart biosensor. The biosensor captures respiratory data and the startup’s platform analyses it using machine learning algorithms
PneumoWave Appoints New Non-Executive Director
PneumoWave, an innovator in the fight against the opioid epidemic with operations in Scotland and the U.S., proudly announces the appointment of Nicola Broughton as its new Non-Executive Director.
PneumoWave Appoints New President and Board of Directors Member
PneumoWave, a digital therapeutics company based in Scotland and the U.S., has announced the appointment of digital medicine and MedTech pioneer Richie Bavasso as the new President of the organization and member of the Board of Directors.
PneumoWave raises £7.5 million Series A to accelerate clinical validation and regulatory submission of respiratory change diagnosis and monitoring platform
PneumoWave today announced the closing of £7.5 m Series A financing which will enable clinical validation and regulatory submission of its biosensor technology platform
Today is Opioid Awareness Day
Today is Opioid Awareness Day. Our Chief Executive Officer and Founder Dr Bruce Henderson has written a powerful opinion piece based on his direct clinical experience treating patients. Learn more about the human cost of the opioid epidemic and the compassion that addicts deserve.
PneumoWave Featured in the Scotsman
We are delighted to be featured in the Scotsman newspaper:
Digital health firm PneumoWave aiming to double workforce on back of £7.5m funding injection
Dr Gary Cooney appointed as Mental Health Lead
Digital health company PneumoWave today announced the appointment of Dr Gary Cooney as Mental Health Lead, with responsibility for the planning and execution of addiction and other mental health-related treatment studies using PneumoWave’s technology platform for diagnosis and monitoring of respiratory changes.
Dundee University start RESCU trial of PneumoWave’s wearable biosensor device aiming to cut opioid overdose deaths
Glasgow, February 28, 2022, Healthtech company PneumoWave today announced that Dundee University is commencing the clinical trial of its wearable device that aims to reduce the growing number of fatal opioid overdoses in Scotland.
PneumoWave & King’s College London Collaborate in Clinical Trial
Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the use of their monitoring platform in a clinical trial led by Professor Sir John Strang at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.
PneumoWave and NHS Greater Glasgow & Clyde Announce Clinical Trial Aiming to Reduce Deaths from Respiratory Depression
Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the commencement of a second clinical trial in partnership with the Research & Innovation Department at NHS Greater Glasgow & Clyde (NHS GG&C).
Rebrand of Altair Medical to PneumoWave
UK based Altair Medical today announced, as part of its ongoing growth story, that it is rebranding to PneumoWave. The name fully reflects the digital therapeutics platform that the company believes will transform respiratory healthcare. In a key step towards commercial launch of the platform, a multi-centre program of clinical trials is currently underway in leading academic and healthcare institutions.
Altair Medical secures $3.1m in Pre-Series A financing
UK based Altair Medical today announced it has secured £2.25m ($3.1m) of Pre-Series A funding to further develop its respiratory sensor and real-time monitoring platform. The service uses AI to detect and alert to adverse events from a range of breathing problems, with the hope of preventing a large number of early deaths.
Storm ID, Altair Medical & NHS GGC develop a respiratory monitoring service for COVID-19 patients in new clinical trial
Scottish digital transformation consultancy Storm ID and Altair Medical have developed a new digital solution to help predict respiratory failure in COVID-19 patients. The solution is being trialled in respiratory failure patients, following funding from Scottish Government Chief Scientist Office.
Altair Medical accelerates development schedule by adopting FDA cleared cloud data management platform
Altair Medical, (“Altair”) aims to revolutionize care for respiratory symptoms and diseases with its advanced, remote respiratory monitoring platform. The company, which was awarded FDA Breakthrough Medical Device designation earlier this year, today announced that it had chosen to transition to Galen Data’s cloud platform to accelerate commercial development of its platform.
Altair medical achieves FDA breakthrough status
Altair Medical, a medical technology company developing a groundbreaking solution to the global opioid crisis, today announce that the US Food and Drug Administration (FDA) has awarded the Company Breakthrough Device designation for its wearable biosensor device.